Global Breakthrough In Treatment Of Dementia 'Within Reach' - Clinical Trial In Scotland Recruiting
Main Category: Alzheimer's / Dementia
Also Included In: Clinical Trials / Drug Trials; Sleep / Sleep Disorders / Insomnia
Article Date: 29 Jul 2010 - 1:00 PDT
| Patient / Public: | ![]() |
4.43 (7 votes) |
| Health Professional: | ![]() |
3.2 (5 votes) |
| Article Opinions: | 2 posts |
A Glasgow-based medical research company is leading a worldwide sleep study which could radically reduce the symptoms associated with dementia.
The groundbreaking trial, conducted by CPS Research, is the first of its kind to investigate the use of sleep hormone melatonin as an add on treatment for dementia. The study is already showing remarkable initial results in volunteers from Scotland.
Melatonin is the natural hormone produced at night to prepare the body for sleep and produced throughout the night to maintain sleep. Older people with dementia often experience difficulties sleeping. Disturbance during the night is frequently the final problem that drives relatives to seek admission to care - a distressing outcome for the patient and their relatives and friends.
Older people produce less melatonin, and researchers with CPS Research observed that patients with dementia in particular produce very little melatonin. Drug company Neurim Pharmaceuticals, led by Nava Zisapel, the world's leading expert on melatonin, has developed Circadin® a pill, to be taken at bedtime, which could potentially alleviate the symptoms of sleeplessness and anxiety frequently associated with Alzheimer's patients. Circadin® mimics the same slow and controlled release of melatonin as occurs in the body of a healthy young adult.
Scotland is the first country to take part in the worldwide trial. Before the study is rolled out internationally, CPS Research is seeking to engage with 100 patients in Scotland to take part in the study over a period of nine months.
Dr Gordon Crawford of CPS Research said, "Dementia can be a shattering condition for patients, their families and friends. CPS Research is extremely encouraged by the positive early results in our world wide melatonin study.
"Melatonin does not currently exist as a treatment for dementia but is registered in Europe and the UK for use in older patients . It has proven remarkably safe and virtually free from side effects.
"With the help of volunteers from Scotland and worldwide we aim to establish that Melatonin helps combat sleeplessness in dementia patients; that a restful and undisturbed sleep helps patients with dementia function better daily and that taking melatonin makes the symptoms of dementia less severe."
To take part in the trial of melatonin in Alzheimer's disease contact CPS Research (Freephone) 0800 731 2647.
Source: CPS Research
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Visitor Opinions In Chronological Order (2)
dementia
posted by kathryn binding on 29 Jul 2010 at 2:16 amReduce the cocktail of drugs that so many people take.Which take minerals and vitamins out of the body and include vitamin supplements in the diet especially thiamine which apparently is often lacking in the diet of the elderly and the effects are memory loss and confusion according to nutrition information.Vitamin and mineral deficiency are not often checked by the NHS but some private practices offer the tests. Probably the main reason for dementia problems is malnutrition!
Oversold study
posted by Chris on 5 Aug 2010 at 6:56 amWhere exactly is the data that melatonin is a 'Global Breakthrough In Treatment Of Dementia', as stated in the title of this article? Melatonin does not treat dementia symptoms, it may help to alleviate some of the secondary consequences of this debilitating and serious disorder, hence the reason it is being investigated as an add-on agent. Stop over-marketing your news pieces, please. The quality of your reporting suffers as a result
Add Your Opinion
All opinions are moderated before being added.
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2010 MediLexicon International Ltd |




